article thumbnail

Biopharma Packaging Requirements: What You Need to Know

Pharma Packaging Solutions

As biopharma products become more common, so must biopharma packaging. Due to the sensitive nature of many biological products, there are strict federal regulations in place to ensure safe packaging and distribution. General Regulations (From Section 112.1) General Regulations (From Section 112.1)

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

A risk-benefit approach underpins the decision-making process to evaluate human drugs, drug/device combinations and advanced therapy medicinal products for licensing of human medicines. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines. About the authors. appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New public Clinical Trials database leads to increased tax & regulatory transparency – risk of supply chain disruption / recall

Pharma Business Blog

Dears Please find hereinafter the latest news related to Clinical Trials in the EU with a respective indirect tax and pharma regulatory licensing impact: 1. The CTIS database is publicly available and leads to increased transparency for indirect tax & pharma regulatory licensing. • What does it mean for you?

article thumbnail

Governors’ Push President on Cannabis Rescheduling But Overlook What Schedule III Would Require

FDA Law Blog

Conceding that they may disagree whether legalization of recreational cannabis or cannabis use is a “net positive,” the governors agreed that the cannabis industry is permanent, that states have implemented “strong regulations,” and supporting the state regulated cannabis marketplace “is essential for the safety of the American people.”

article thumbnail

MIOTIFY platform for digital health products clears AZ road test

pharmaphorum

Teasing out complex relationships within data lies at the heart of any digital health intervention, but finding the algorithms to do so reliably – and making sure they will be acceptable to regulators – can be a challenge. The algorithms used in healthcare are becoming more complex as well.

article thumbnail

Animals Need Drugs Too, But Not Without CVM Approval

FDA Law Blog

Specifically, CVM ensures that animal drugs are safe and effective, properly made, and adequately labeled and packaged; food-producing animals only take drugs that would be safe for humans to consume; pet foods and additives are safe; and educates the public, monitors the market, and encourages development of new animal health products.

Drugs 59
article thumbnail

PDUFA VII: More Changes Coming in the Latest Reauthorization

Camargo

For a standard new drug application (NDA) for a new molecular entity (NME) or original biologic license application (BLA) pre-approval, the FDA will communicate details on anticipated PMRs to the applicant no later than eight weeks prior to the PDUFA action date. Receipt of Background Package. Response Time. calendar days).